Cargando…

Validation of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO(©))

This study demonstrates the quantitative characteristics of the first patient‐reported outcome (PRO) tool developed for patients with nontransfusion‐dependent β‐thalassemia (NTDT), the NTDT‐PRO(©). A multicenter validation study was performed over 24 weeks, involving 48 patients from Italy, Lebanon,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taher, Ali, Cappellini, Maria Domenica, Viprakasit, Vip, Sutcharitchan, Pranee, Mahmoud, Dalia, Laadem, Abderrahmane, Khan, Anzalee, Gwaltney, Chad, Harding, Gale, Attie, Kenneth, Zhang, Xiaosha, Zou, Jun, Pariseau, Joseph, Henry Hu, X., Kattamis, Antonis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587834/ https://www.ncbi.nlm.nih.gov/pubmed/30394570 http://dx.doi.org/10.1002/ajh.25344

Ejemplares similares

Development of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO(©))
por: Taher, Ali, et al.
Publicado: (2018)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
por: Taher, Ali T., et al.
Publicado: (2013)

Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm
por: Musallam, Khaled M., et al.
Publicado: (2022)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
por: Musallam, Khaled M, et al.
Publicado: (2023)

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
por: Taher, Ali T, et al.
Publicado: (2023)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
por: Taher, Ali T, et al.
Publicado: (2013)

Treating iron overload in patients with non-transfusion-dependent thalassemia
por: Taher, Ali T, et al.
Publicado: (2013)

Changing patterns in the epidemiology of β‐thalassemia
por: Kattamis, Antonis, et al.
Publicado: (2020)

Novel Approach to Reactive Oxygen Species in Nontransfusion-Dependent Thalassemia
por: Tyan, Paul I., et al.
Publicado: (2014)

Iron overload across the spectrum of non‐transfusion‐dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
por: Porter, John B., et al.
Publicado: (2016)

Marital status and paternity in patients with Transfusion-Dependent Thalassemia (TDT) and Non Transfusion-Dependent Thalassemia (NTDT): an ICET - A survey in different countries
por: De Sanctis, Vincenzo, et al.
Publicado: (2019)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia
por: Winichakoon, Poramed, et al.
Publicado: (2015)

Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease
por: Ferraresi, Marta, et al.
Publicado: (2023)

Justification of Universal Iron Supplementation for Infants 6–12 months in Regions with a High Prevalence of Thalassemia
por: Sinlapamongkolkul, Phakatip, et al.
Publicado: (2023)

Cardio-protective effect of regular transfusion in children with non-transfusion dependent thalassemia (NTDT): A cohort study
por: Al Senaidi, Khalfan, et al.
Publicado: (2022)

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study
por: Cappellini, Maria Domenica, et al.
Publicado: (2019)

Right in time: Mitapivat for the treatment of anemia in α- and β-thalassemia
por: Musallam, Khaled M., et al.
Publicado: (2022)

Non-transfusion dependent hemoglobin E/β thalassemia had high prevalence of vitamin D deficiency than more severe patients who received regular blood transfusion and iron chelation therapy
por: Nakavachara, Pairunyar, et al.
Publicado: (2013)

Coagulopathy in Beta-Thalassemia: Current Understanding and Future Perspectives
por: Cappellini, M. Domenica, et al.
Publicado: (2009)

An urgent need for improving thalassemia care due to the wide gap in current real-life practice and clinical practice guidelines
por: Ekwattanakit, Supachai, et al.
Publicado: (2021)

β-Thalassemia: New Therapeutic Modalities, Genetics, Complications, and Quality of Life
por: Karimi, Mehran, et al.
Publicado: (2012)

EF Bart's Disease with Coinheritance of Gγ-XmnI and Aγ-Globin Polymorphisms: A Case of Nontransfusion-Dependant Thalassemia
por: Laks, Kane M., et al.
Publicado: (2020)

PB2535: TRIAL IN PROGRESS: A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUSPATERCEPT TO TREAT ANEMIA IN ADULTS WITH ALPHA-THALASSEMIA
por: Viprakasit, Vip, et al.
Publicado: (2023)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

Association of osteoporosis and sarcopenia with fracture risk in transfusion-dependent thalassemia
por: Thavonlun, Suttana, et al.
Publicado: (2023)

P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIAL
por: Coates, Thomas D., et al.
Publicado: (2023)

P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K, et al.
Publicado: (2022)

Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition
por: Viprakasit, Vip, et al.
Publicado: (2014)

Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management
por: Sleiman, Joseph, et al.
Publicado: (2018)

2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia
por: Farmakis, Dimitrios, et al.
Publicado: (2022)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Prevalence of left ventricular diastolic dysfunction by cardiac magnetic resonance imaging in thalassemia major patients with normal left ventricular systolic function
por: Chinprateep, Benjaporn, et al.
Publicado: (2019)

Feasibility of and barriers to thalassemia screening in migrant populations: a cross-sectional study of Myanmar and Cambodian migrants in Thailand
por: Xu, Julia Z., et al.
Publicado: (2021)

Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2022)

Does Splenectomy Influence the Development of Hypothyroidism in Transfusion Dependent Thalassemia Patients? A Retrospective Study
por: Skafida, Myrto, et al.
Publicado: (2019)

EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update
por: Iolascon, Achille, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_seuf0i05bs5qsfsuu0b7ag8can